Most new antimicrobial agents have been developed and assessed in adult patients, although a few have been for children. Pharmacokinetic specificity for different age categories (neonates, infants, children and adolescents) implies that studies for all of these groups of patients should be undertaken. Specific pathologies have been observed in paediatrics, and efficacy cannot be extrapolated from adult studies. Finally, as children are developing organisms, toxicity cannot be evaluated in children from adults trials.
© Lippincott-Raven Publishers.